Sedat Gül/LinkedIn
Sep 5, 2026, 02:44
Sedat Gül: Is It Time to Reconsider the 24-Hour Antiplatelet Delay After Thrombolysis?
Sedat Gül, Assistant Professor at University of Nebraska Medical Center, shared a post on LinkedIn:
“I had the opportunity to comment in Annals of Internal Medicine on the TAPIS trial, which revisits the timing of antiplatelet therapy after thrombolysis in acute ischemic stroke.
While the findings may not be directly generalizable to the U.S. stroke population, TAPIS provides solid safety data and a signal of potential benefit with earlier initiation of antiplatelet therapy.”
Stay updated with Hemostasis Today.
-
Oct 20, 2026, 05:46Jan T. Kielstein: DNP Poisoning and Hemoadsorption The Limits of Rescue Therapy
-
Oct 20, 2026, 05:33Giulia Di Paolo: Connecting Plasma Donation to the Patients Who Depend on It
-
Oct 20, 2026, 05:20James Knowles: Exploring Plasma Manufacturing and Strengthening Industry Collaboration
-
Oct 20, 2026, 05:11Giuseppe Lippi։ Understanding Liver Test Abnormalities After AAV Gene Therapy
-
Oct 20, 2026, 05:02Sanam Loghavi: Test Your Hematology Knowledge at ASH 2026!
-
Oct 20, 2026, 04:13Ifeanyichukwu Ifechidere: DOACs Are Not the Answer to Every Anticoagulation Question
-
Oct 20, 2026, 04:04Sadia Kamal: Honored to Receive the Outstanding Abstract Award at the 20th Midwest Platelet Conference
-
Oct 20, 2026, 04:03Yu-Hsuan Chen: One Antibody, Two Diseases from FcRn Biology to Clinical Translation
-
Oct 20, 2026, 03:49Domenico Simone Castiello: Rethinking Prolonged DAPT in Multivessel PCI – Insights from the DAPT-MVD Trial